ACADIA Pharmaceuticals Inc (ACAD) stock news · P/E 15, rev $576.0M
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
This ACAD news page leads with what ACADIA Pharmaceuticals Inc filed — not a scraped headline mill.
No cached 8-K sentence for ACAD yet. We will not pad this page with generic market recap.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the ACAD stock page; for the tape open the quote page.
Not investment advice.